Exelixis Files Patent Complaint Against Cipla's Cancer Treatment
By Sabela Ojea
Exelixis has filed a complaint for an alleged patent infringement against Cipla and its abbreviated new drug application that is now pending with the Food and Drug Administration.
The company said on Friday that it's seeking an order to make the effective date of any FDA approval of Cipla's abbreviated new drug application after the expiration of a number of its patents, the latest of which expires on Feb. 10, 2032.
Exelixis is also requesting and equitable relief enjoining Cipla from infringing its patents, the company said.
Cipla's abbreviated new drug application now requests approval to market generic versions of its anti-cancer treatment Cabometyx in tablets with 20 milligrams and 40 milligrams dosage strengths prior to the expiration of some patents.
The company on Thursday filed the complaint in the U.S. District Court for the District of Delaware.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
May 10, 2024 17:18 ET (21:18 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks